White patients with acute myeloid leukemia (AML) appear to benefit more from recent therapy developments compared with non-Hispanic Black patients in the United States, according to data published in Cancer Discovery.1
Specifically, the investigators explain that socioeconomic factors and differences in disease biology both contribute to the survival disparities discovered between each group of patients in this research.
“Our study shows that survival disparities for Black [patients with AML] persist even in the era of improved understanding of the disease and refined genomic classification of AML,” wrote the investigators. “This is particularly noticeable for younger patients, who, in general, have a higher chance of cure.”
Using data compiled from the Surveillance Epidemiology and End Results (SEER) Program, the research team analyzed survival of 25,523 Non-Hispanic Black and…
